<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open-access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5298248</article-id><article-id pub-id-type="pmid">28178281</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0171124</article-id><article-id pub-id-type="publisher-id">PONE-D-16-36615</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Control</subject><subj-group><subject>Antimicrobial Resistance</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Antimicrobial Resistance</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Geographical Locations</subject><subj-group><subject>Africa</subject><subj-group><subject>Kenya</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Geographical Locations</subject><subj-group><subject>Africa</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Molecular Biology Assays and Analysis Techniques</subject><subj-group><subject>Phylogenetic Analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Molecular Biology Assays and Analysis Techniques</subject><subj-group><subject>Phylogenetic Analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>HIV diagnosis and management</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Viral Transmission and Infection</subject><subj-group><subject>Viral Load</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Surveillance of HIV-1 <italic>pol</italic> transmitted drug resistance in acutely and recently infected antiretroviral drug-na&#x000ef;ve persons in rural western Kenya</article-title><alt-title alt-title-type="running-head">Transmitted drug resistance in rural western Kenya</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Onywera</surname><given-names>Harris</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Maman</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Inzaule</surname><given-names>Seth</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Auma</surname><given-names>Erick</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Were</surname><given-names>Kennedy</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fredrick</surname><given-names>Harrison</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Owiti</surname><given-names>Prestone</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Opollo</surname><given-names>Valarie</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Etard</surname><given-names>Jean-Fran&#x000e7;ois</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mukui</surname><given-names>Irene</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Andrea A.</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zeh</surname><given-names>Clement</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Center for Global Health Research (CGHR), Kenya Medical Research Institute (KEMRI), Kisumu, Kenya</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Epicentre, M&#x000e9;decins Sans Fronti&#x000e8;res (MSF), Paris, France</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>TransVIHMI IRD UMI 233 &#x02013;INSERM U 1175 &#x02013;Universit&#x000e9; de Montpellier, Montpellier, France</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>National AIDS and STI Control Programme (NASCOP), Ministry of Health, Nairobi, Kenya</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>US Centers for Disease Control and Prevention (CDC), Nairobi, Kenya</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>US Centers for Disease Control and Prevention (CDC), Kisumu, Kenya</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Men&#x000e9;ndez-Arias</surname><given-names>Luis</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Universidad Autonoma de Madrid Centro de Biologia Molecular Severo Ochoa, SPAIN</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> DM CZ.</p></list-item><list-item><p><bold>Data curation:</bold> HO DM SI EA HF CZ.</p></list-item><list-item><p><bold>Formal analysis:</bold> HO DM SI EA KW HF PO CZ.</p></list-item><list-item><p><bold>Funding acquisition:</bold> DM.</p></list-item><list-item><p><bold>Investigation:</bold> HO KW HF VO.</p></list-item><list-item><p><bold>Methodology:</bold> DM CZ.</p></list-item><list-item><p><bold>Project administration:</bold> DM CZ.</p></list-item><list-item><p><bold>Resources:</bold> DM CZ.</p></list-item><list-item><p><bold>Supervision:</bold> SI CZ.</p></list-item><list-item><p><bold>Validation:</bold> HO KW HF VO.</p></list-item><list-item><p><bold>Visualization:</bold> HO DM SI EA CZ.</p></list-item><list-item><p><bold>Writing &#x02013; original draft:</bold> HO SI EA.</p></list-item><list-item><p><bold>Writing &#x02013; review &#x00026; editing:</bold> HO DM SI EA KW HF PO VO J-FE IM AAK CZ.</p></list-item></list>
</p></fn><fn fn-type="other" id="econtrib001"><p>&#x02021; These authors also contributed equally to this work.</p></fn><corresp id="cor001">* E-mail: <email>cbz2@cdc.gov</email> (CZ); <email>do79harris@gmail.com</email> (HO)</corresp></author-notes><pub-date pub-type="epub"><day>8</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>2</issue><elocation-id>e0171124</elocation-id><history><date date-type="received"><day>12</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2017</year></date></history><permissions><license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0171124.pdf"/><abstract><p>HIV-1 transmitted drug resistance (TDR) is of increasing public health concern in sub-Saharan Africa with the rollout of antiretroviral (ARV) therapy. Such data are, however, limited in Kenya, where HIV-1 drug resistance testing is not routinely performed. From a population-based household survey conducted between September and November 2012 in rural western Kenya, we retrospectively assessed HIV-1 TDR baseline rates, its determinants, and genetic diversity among drug-na&#x000ef;ve persons aged 15&#x02013;59 years with acute HIV-1 infections (AHI) and recent HIV-1 infections (RHI) as determined by nucleic acid amplification test and both Limiting Antigen and BioRad avidity immunoassays, respectively. HIV-1 <italic>pol</italic> sequences were scored for drug resistance mutations using Stanford HIVdb and WHO 2009 mutation guidelines. HIV-1 subtyping was computed in MEGA6. Eighty seven (93.5%) of the eligible samples were successfully sequenced. Of these, 8 had at least one TDR mutation, resulting in a TDR prevalence of 9.2% (95% CI 4.7&#x02013;17.1). No TDR was observed among persons with AHI (n = 7). TDR prevalence was 4.6% (95% CI 1.8&#x02013;11.2) for nucleoside reverse transcriptase inhibitors (NRTIs), 6.9% (95% CI 3.2&#x02013;14.2) for non- nucleoside reverse transcriptase inhibitors (NNRTIs), and 1.2% (95% CI 0.2&#x02013;6.2) for protease inhibitors. Three (3.4% 95% CI 0.8&#x02013;10.1) persons had dual-class NRTI/NNRTI resistance. Predominant TDR mutations in the reverse transcriptase included K103N/S (4.6%) and M184V (2.3%); only M46I/L (1.1%) occurred in the protease. All the eight persons were predicted to have different grades of resistance to the ARV regimens, ranging from potential low-level to high-level resistance. HIV-1 subtype distribution was heterogeneous: A (57.5%), C (6.9%), D (21.8%), G (2.3%), and circulating recombinant forms (11.5%). Only low CD4 count was associated with TDR (p = 0.0145). Our findings warrant the need for enhanced HIV-1 TDR monitoring in order to inform on population-based therapeutic guidelines and public health interventions.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>M&#x000e9;decins Sans Fronti&#x000e8;res (MSF)</institution></funding-source><principal-award-recipient><name><surname>Maman</surname><given-names>David</given-names></name></principal-award-recipient></award-group><funding-statement>This work was funded by the M&#x000e9;decins Sans Fronti&#x000e8;res (MSF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="14"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files. All 87 HIV-1 sequence files are available from the National Center for Biotechnology Information GenBank (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/genbank/">https://www.ncbi.nlm.nih.gov/genbank/</ext-link>) GenBank database (accession numbers KX790964-KX7910050).</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data availability</title><p>All relevant data are within the paper and its Supporting Information files. All 87 HIV-1 sequence files are available from the National Center for Biotechnology Information GenBank (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/genbank/">https://www.ncbi.nlm.nih.gov/genbank/</ext-link>) GenBank database (accession numbers KX790964-KX7910050).</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Highly active antiretroviral therapy (HAART) has been effective at treating HIV infection and improving overall health and survival, but constant viral evolution continues to result in drug resistance [<xref rid="pone.0171124.ref001" ref-type="bibr">1</xref>]. Of the 28.3 million HIV-infected persons eligible for antiretroviral therapy (ART) in resource-limited settings (RLS), only 34% are on ART under the 2012 World Health Organization (WHO) treatment guidelines [<xref rid="pone.0171124.ref002" ref-type="bibr">2</xref>]. Based on the 2013 Kenya AIDS Indicator Survey, 58% of people living with HIV/AIDS (PLWHA) aged 15&#x02013;64 years in Kenya were eligible for ART, but only 63% of them were found to have been initiated [<xref rid="pone.0171124.ref003" ref-type="bibr">3</xref>]. Primary, or transmitted drug resistance (TDR) [<xref rid="pone.0171124.ref004" ref-type="bibr">4</xref>] has been of a rising concern in sub-Saharan Africa (sSA) with scale-up and long-term use of antiretrovirals (ARVs) [<xref rid="pone.0171124.ref005" ref-type="bibr">5</xref>&#x02013;<xref rid="pone.0171124.ref007" ref-type="bibr">7</xref>]. It accounts for 8&#x02013;22% among newly HIV-infected persons in the majority of the regions of the world [<xref rid="pone.0171124.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pone.0171124.ref013" ref-type="bibr">13</xref>]. TDR may complicate the management of PLWHA [<xref rid="pone.0171124.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0171124.ref015" ref-type="bibr">15</xref>], and as proposed by Hassan et al. and Nichols et al., it may reverse the benefits made from global scale-up of ART [<xref rid="pone.0171124.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0171124.ref017" ref-type="bibr">17</xref>].</p><p>As access to HAART is rolled out globally, WHO Global HIV Resistance Network recommends periodic monitoring of TDR (among acutely and recently infected drug-na&#x000ef;ve persons [mean seroconversion period: 180 days [<xref rid="pone.0171124.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0171124.ref018" ref-type="bibr">18</xref>]]) in RLS [<xref rid="pone.0171124.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0171124.ref020" ref-type="bibr">20</xref>] where there is limited availability and treatment options of ARVs, hence ensuring effective treatment [<xref rid="pone.0171124.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0171124.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0171124.ref022" ref-type="bibr">22</xref>]. TDR has a potential to compromise treatment [<xref rid="pone.0171124.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0171124.ref022" ref-type="bibr">22</xref>&#x02013;<xref rid="pone.0171124.ref024" ref-type="bibr">24</xref>] despite apposite prescribing and adherence [<xref rid="pone.0171124.ref015" ref-type="bibr">15</xref>]. In resource-rich settings (RRS), moderate levels of TDR have been observed [<xref rid="pone.0171124.ref004" ref-type="bibr">4</xref>] but are either stabilizing or declining due to universal availability of highly efficacious drugs [<xref rid="pone.0171124.ref025" ref-type="bibr">25</xref>]. Many regions in sSA have low to moderate TDR levels, but urban sites have begun to show an increase [<xref rid="pone.0171124.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0171124.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0171124.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0171124.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0171124.ref026" ref-type="bibr">26</xref>&#x02013;<xref rid="pone.0171124.ref033" ref-type="bibr">33</xref>]. Data on TDR in RLS are scarce, with drug resistance testing not routinely performed [<xref rid="pone.0171124.ref021" ref-type="bibr">21</xref>].</p><p>WHO recommends that TDR should be assessed periodically among newly infected persons who are identified using a set of criteria that is likely to select persons who have AHI/RHI. These include drug-na&#x000ef;ve young (&#x0003c;25 years of age) and newly HIV diagnosed primagravida women visiting antenatal clinics, persons visiting voluntary counselling and testing/sexually transmitted infections clinics, or in high-risk populations, although limitations exist [<xref rid="pone.0171124.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0171124.ref013" ref-type="bibr">13</xref>]. The use of these criteria is limiting as most of the incident cases are omitted from the survey [<xref rid="pone.0171124.ref020" ref-type="bibr">20</xref>]. Some studies in RRS evaluate TDR among persons with AHI, but this method is difficult to perform, and takes time to attain a sufficient number of persons [<xref rid="pone.0171124.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0171124.ref013" ref-type="bibr">13</xref>]. In addition to routine monitoring of HIV prevalence, WHO recommends evaluating HIV incidence in high prevalence settings through population-based surveys by laboratory-based assays for AHI/RHI [<xref rid="pone.0171124.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0171124.ref034" ref-type="bibr">34</xref>]. Cross-sectional incidence surveys are not dependent on patient follow-up and rapidly offer up-to-date information that is required for efficient public health responses [<xref rid="pone.0171124.ref035" ref-type="bibr">35</xref>]. Moreover, such surveys may additionally be used to determine TDR.</p><p>Characterizing HIV drug resistance using the AHI/RHI method is likely to give a more representative estimate [<xref rid="pone.0171124.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0171124.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0171124.ref034" ref-type="bibr">34</xref>,<xref rid="pone.0171124.ref036" ref-type="bibr">36</xref>]. We assessed HIV-1 TDR level in treatment-na&#x000ef;ve persons with AHI/RHI in an ARV-exposed rural setting in western Kenya that has both high HIV incidence and prevalence [<xref rid="pone.0171124.ref037" ref-type="bibr">37</xref>,<xref rid="pone.0171124.ref038" ref-type="bibr">38</xref>].</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Study design and population</title><p>The TDR survey was nested within the Ndhiwa HIV Impact in Population Survey (NHIPS) [<xref rid="pone.0171124.ref037" ref-type="bibr">37</xref>], an incidence study conducted in Ndhiwa sub-county of Homa Bay County in Nyanza region of western Kenya, between September and November 2012. A multistage cluster sampling method was used to recruit study participants aged 15&#x02013;59 years from 3,302 randomly selected households. Those who volunteered to participate in the study were interviewed and tested for HIV using a serial rapid testing algorithm. CD4 cell count, recency of HIV infection, and viral load for those who tested HIV positive were measured using validated laboratory procedures. Of the 6,076 persons eligible for NHIPS, 1,457 (24.1%) were confirmed as HIV-1 infected [<xref rid="pone.0171124.ref037" ref-type="bibr">37</xref>]. We collected the baseline characteristics of HIV-1 infected persons from the NHIPS records, and drug-na&#x000ef;ve cases with AHI/RHI infection (n = 93) were included in the study.</p></sec><sec id="sec004"><title>Ethical considerations</title><p>The NHIPS was approved by the Ethics Committee of the Kenya Medical Research Institute (KEMRI), Kenya; the Committee for the Protection of Persons, Saint-Germain-en-Laye, France; and the Division of HIV/AIDS Prevention (DHAP) under the Centers for Disease Control and Prevention (CDC), Atlanta, US. All the participants provided written informed consent to be involved in the study. For participants younger than 18 years of age but older than 15 years of age and not a mature minor, the study details were explained to at least one parent/guardian for parental written permission and then to the minor for written consent. Mature minors are defined in the Kenya National voluntary counselling and testing guidelines as persons under 18 who are married, pregnant, parents, engage in behaviour that put them at HIV transmission risk or are child sex workers. However, mature minors were strongly advised to speak with and involve their parents/guardians in the study participation process if they felt it was safe to do so. All minors, unless matured, had parental/guardian written permission and also provided written consent.</p></sec><sec id="sec005"><title>HIV status and duration of recency</title><p>HIV status was determined using a parallel testing algorithm of two HIV rapid tests: Uni-Gold<sup>TM</sup> HIV (Trinity Biotech, Ireland) and Determine<sup>TM</sup> HIV-1/2 (Abbott Laboratories<sup>&#x000ae;</sup>, Tokyo, Japan). The recency of HIV infection was established by two serological assays: the Limiting Antigen (LAg) (Maxim Biomedical, Inc., Rockville, USA) and BioRad Avidity Index (AI) (Bio-Rad Laboratories, WA, USA) enzyme immunoassays (EIA). Assay cut-offs for the duration of recency were 1.5 normalized optical density (ODn) and 30% AI, respectively, for the two serological assays. Any sample that was identified as recently infected from either assay, was included in the study. Persons with AHI were identified by negative result with Determine<sup>TM</sup> (Abbott Laboratories<sup>&#x000ae;</sup>, Tokyo, Japan) and positive result with nucleic acid amplification test (NAAT) [<xref rid="pone.0171124.ref037" ref-type="bibr">37</xref>]. CD4 cell count and viral load were measured using PIMA point-of-care CD4 Analyzer (Alere, Inc., Waltham, MA, USA) and COBAS AmpliPrep/COBAS TaqMan v2.0 (Roche Molecular Systems, Branchburg, NJ, USA), respectively, according to the manufacturers&#x02019; instructions.</p></sec><sec id="sec006"><title>Genotypic drug resistance profiling</title><p>Dried blood spots (DBS) and plasma from persons with AHI and RHI, respectively, were used for HIV-1 genotyping. The partial <italic>pol</italic> gene (protease, PR: codons 6&#x02013;99; reverse transcriptase, RT: codons 1&#x02013;251) of the HIV-1 isolates was sequenced using a CDC-validated in-house genotyping assay utilizing a standard sequencing chemistry as previously described [<xref rid="pone.0171124.ref039" ref-type="bibr">39</xref>]. This was performed on ABI PRISM 3130<italic>xl</italic> Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Sequence chromatograms were analyzed by RECall v2.0 Software using HIV-1 HXB2 sequence as the reference [<xref rid="pone.0171124.ref040" ref-type="bibr">40</xref>], and checked for cross-contamination by phylogenetic analyses (<ext-link ext-link-type="uri" xlink:href="http://www.phylogeny.fr/">www.phylogeny.fr/</ext-link>) [<xref rid="pone.0171124.ref041" ref-type="bibr">41</xref>]. TDR was defined according to the Stanford HIVdb&#x02019;s (<ext-link ext-link-type="uri" xlink:href="http://hivdb.stanford.edu/">hivdb.stanford.edu/</ext-link>) Calibrated Population Resistance (CPR) v6.0, and WHO 2009 Mutation List [<xref rid="pone.0171124.ref042" ref-type="bibr">42</xref>]. We employed the WHO TDR surveillance classification scale for prevalence: low (&#x0003c;5%), intermediate/moderate (5&#x02013;15%) and high (&#x0003e;15%) [<xref rid="pone.0171124.ref020" ref-type="bibr">20</xref>]. The predicted ARV drug responses in persons with TDR was assessed by the Stanford HIVdb v7.0 that is normalized to five drug response levels based on net drug score: Susceptible (&#x02264;9), Potential low-level resistance (10&#x02013;14), Low-level resistance (15&#x02013;30), Intermediate resistance (31&#x02013;59), and High-level resistance (&#x02265;60) [<xref rid="pone.0171124.ref043" ref-type="bibr">43</xref>].</p></sec><sec id="sec007"><title>Phylogenetic analyses</title><p>HIV-1 subtyping was statistically done by maximum likelihood (ML) phylogenetic reconstruction in MEGA6; a bootstrap of 1000 replicates was used to generate the consensus evolutionary tree and assess the strength of cluster from each node. Nineteen known reference sequences from Los Alamos National Laboratory HIV sequence database (<ext-link ext-link-type="uri" xlink:href="http://hiv-web.lanl.gov/">http://hiv-web.lanl.gov</ext-link>) of common HIV-1 subtypes in Kenya were included to deduce the subtypes of the ingroup. HIV-1 subtype K was used as an outgroup species. Multiple sequence alignment was achieved by MUSCLE program within MEGA6. The alignment was trimmed to a length of 1035 bp. According to the Bayesian Information Criterion scores of 24 different nucleotide substitution models, the Hasegawa-Kishino-Yano with discrete Gamma distribution (0.42) (for non-uniformity of evolutionary rates among sites: 5 rate categories) and Invariable sites (0.54) (HKY+G+I) was selected as the ideal model to describe the substitution pattern. All positions containing gaps or missing data were completely eliminated. Subtree-Pruning-Regrafting&#x02013;Extensive (SPR level 5) method was used as the ML heuristic option for tree inference due to its effectiveness. The initial tree was automatically generated by BioNJ. A moderate branch swap filter was set in order to allow for a semi-stringent exhaustive optimization of the branch lengths and improvements in log likelihood values [<xref rid="pone.0171124.ref044" ref-type="bibr">44</xref>].</p></sec><sec id="sec008"><title>Statistical analyses</title><p>The overall TDR and drug-specific TDR prevalence were assessed in accordance with WHO standards [<xref rid="pone.0171124.ref020" ref-type="bibr">20</xref>] and the 95% CI computed based on Wilson&#x02019;s approach [<xref rid="pone.0171124.ref045" ref-type="bibr">45</xref>]. Associations of TDR with categorical (gender, recency of HIV-1 infection, and HIV-1 subtype) and continuous (participant&#x02019;s age, CD4 cell count, and viral load) variables were computed by Fisher&#x02019;s exact and Wilcoxon signed-rank tests, respectively. The overall TDR prevalence and patterns were descriptively compared to previous surveys in East Africa.</p></sec></sec><sec sec-type="results" id="sec009"><title>Results</title><sec id="sec010"><title>Population baseline characteristics</title><p>Of the 6,076 eligible persons, 1,457 (24.1% after adjustment) were confirmed as HIV-1 infected, of which 93 (6.4%) were either acutely (n = 7) or recently-infected (n = 86) and ARV drug-na&#x000ef;ve by self-report. None of the persons included in the survey reported being aware of or exposed to prophylaxis for prevention of mother-to-child transmission (PMTCT). <xref rid="pone.0171124.t001" ref-type="table">Table 1</xref> shows the key baseline characteristics of the 93 persons with AHI/RHI included in the analysis.</p><table-wrap id="pone.0171124.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0171124.t001</object-id><label>Table 1</label><caption><title>Demographic and clinical characteristics of acutely and recently HIV-1 infected antiretroviral-na&#x000ef;ve persons in the Ndhiwa cohort, Kenya, 2012.</title></caption><alternatives><graphic id="pone.0171124.t001g" xlink:href="pone.0171124.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" colspan="2" rowspan="1">Baseline Characteristics</th><th align="center" rowspan="1" colspan="1">All Persons (n = 93)</th></tr></thead><tbody><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Duration of Infection</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Recently Infected</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">86 (92.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Acutely Infected</td><td align="center" rowspan="1" colspan="1">7 (8.0%)</td></tr><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Median Age (years)</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"/><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">29 (IQR 23&#x02013;37)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender</td><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">26 (28%)</td></tr><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"/><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Female</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">67 (72%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median CD4<sup>+</sup> T-Cell Count (cells/&#x003bc;l)</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">550 (IQR 387&#x02013;698)</td></tr><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Viral Load (copies/ml)</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Recently Infected</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">4.68 log<sub>10</sub> (IQR 4.13&#x02013;5.21)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Acutely Infected</td><td align="center" rowspan="1" colspan="1">6.18 log<sub>10</sub> (IQR 5.89&#x02013;7.00)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>IQR&#x02014;Interquartile Range.</p></fn></table-wrap-foot></table-wrap><p>The median age was 29 years (interquartile range (IQR) 24&#x02013;37), and 72% (67) were female. The median CD4 cell count and viral load were 550 cells/&#x003bc;L (IQR 387&#x02013;698) and 4.68 log<sub>10</sub> copies/mL (IQR 4.13&#x02013;5.21), respectively. Median viral load for persons with AHI was 6.18 log<sub>10</sub> copies/mL (IQR 5.89&#x02013;7.00).</p></sec><sec id="sec011"><title>Drug resistance patterns</title><p>Our genotyping success rate was 94% (n = 87). Six (6%) samples (including two DBS) failed to amplify due to inadequate sample volume, poor sample integrity, or low viral load and were therefore excluded from the analyses. Eight of the genotyped samples had at least one TDR mutation (TDRM) resulting in an overall TDR prevalence of 9.2% (95% CI 4.7&#x02013;17.1). The distribution of class-specific TDRMs in the eight persons with TDR was quantified. Five (62.5%) had only one any class-specific TDRM (i.e., 1 person with PI TDRM, 1 with NRTI TDRM, and 3 with NNRTI TDRMs) while the rest had dual-class NRTI/NNRTI resistance. Class-specific TDR prevalence was 4.6% (95% CI 1.8&#x02013;11.2) for NRTIs, 6.9% (95% CI 3.2&#x02013;14.2) for NNRTIs, and 1.2% (95% CI 0.2&#x02013;6.2) for PIs. In total, 10 TDRMs were observed: one in the protease (PR) gene and 9 in the reverse transcriptase (RT) gene. The dominant TDRMs in the RT gene were K103N/S (n = 4, 4.6%) and M184V (n = 2, 2.3%), while in the PR gene only M46I/L (n = 1, 1.1%) occurred. We found no TDR among persons with AHI.</p></sec><sec id="sec012"><title>TDR prevalence and pattern comparison</title><p>We further compared the observed TDR with those observed in other regions of East Africa (<xref rid="pone.0171124.t002" ref-type="table">Table 2</xref>).</p><table-wrap id="pone.0171124.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0171124.t002</object-id><label>Table 2</label><caption><title>Prevalence of TDR in selected regions of East Africa.</title></caption><alternatives><graphic id="pone.0171124.t002g" xlink:href="pone.0171124.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">Region</th><th align="center" rowspan="1" colspan="1">TDR Prevalence (%)</th><th align="center" rowspan="1" colspan="1">Year(s) of Assessment</th><th align="center" rowspan="1" colspan="1">HIV-1 TDR Eligibility among ARV-Na&#x000ef;ve Persons</th></tr></thead><tbody><tr><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1"><bold>Kenya</bold></td><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1">Nairobi</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">7.5</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">2005</td><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1">HIV-infected persons aged &#x02265;18 years who presented themselves for treatment at a clinic. No history of ARV use by self-report [<xref rid="pone.0171124.ref032" ref-type="bibr">32</xref>].</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>Kenya</bold></td><td align="justify" rowspan="1" colspan="1">Nairobi</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">2007/09</td><td align="justify" rowspan="1" colspan="1">HIV-infected persons aged &#x02265;18 years, eligible to start first-line ARV therapy in accordance with the treatment guidelines. All pregnant women were excluded [<xref rid="pone.0171124.ref027" ref-type="bibr">27</xref>].</td></tr><tr><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1"><bold>Kenya</bold></td><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1">Mombasa</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">4.9</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">2007/09</td><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1">HIV-infected persons aged &#x02265;18 years, eligible to start first-line ARV therapy in accordance with the treatment guidelines. All pregnant women were excluded [<xref rid="pone.0171124.ref027" ref-type="bibr">27</xref>].</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>Kenya</bold></td><td align="justify" rowspan="1" colspan="1">Mombasa</td><td align="center" rowspan="1" colspan="1">13.2</td><td align="center" rowspan="1" colspan="1">2009/10</td><td align="justify" rowspan="1" colspan="1">Newly diagnosed HIV-infected persons aged 18&#x02013;25 years, or laboratory evidence of HIV recency (defined by a positive antibody test with a negative antibody test in the past 1 year, or an indeterminate/negative antibody test with detectable HIV RNA or p24 antigen) [<xref rid="pone.0171124.ref026" ref-type="bibr">26</xref>].</td></tr><tr><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1"><bold>Kenya</bold></td><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1">Kilifi</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">1.1</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">2008/10</td><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1">Cross-sectional pretreatment HIVDR assessment from HIV-infected persons aged &#x0003e;15 years [<xref rid="pone.0171124.ref016" ref-type="bibr">16</xref>].</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>Kenya</bold></td><td align="justify" rowspan="1" colspan="1"><bold>Ndhiwa</bold></td><td align="center" rowspan="1" colspan="1"><bold>9.2</bold></td><td align="center" rowspan="1" colspan="1"><bold>2012</bold></td><td align="justify" rowspan="1" colspan="1">See our <bold><xref ref-type="sec" rid="sec002">Methods</xref></bold> section: Subsections&#x02013;Study design and population, and HIV Status [<xref rid="pone.0171124.ref037" ref-type="bibr">37</xref>] and duration of recency.</td></tr><tr><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1"><bold>Tanzania</bold></td><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1">Dar es Salaam</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">&#x0003c;5.0</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">2005/06</td><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1">HIV-infected primagravidas aged &#x0003c;25 years in the HIV sentinel surveillance among pregnant women attending antenatal clinic [<xref rid="pone.0171124.ref028" ref-type="bibr">28</xref>].</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>Uganda</bold></td><td align="justify" rowspan="1" colspan="1">Kampala</td><td align="center" rowspan="1" colspan="1">7.0</td><td align="center" rowspan="1" colspan="1">2002/04</td><td align="justify" rowspan="1" colspan="1">HIV-infected persons from a HIV RNA monitoring study. No history of ARV use by self-report [<xref rid="pone.0171124.ref029" ref-type="bibr">29</xref>].</td></tr><tr><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1"><bold>Uganda</bold></td><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1">Entebbe</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">0.0</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">2006/07</td><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1">HIV-infected primagravidas aged 13&#x02013;22 years with no previous positive HIV test, and &#x02265;500 CD4 cell count (cells/mL) [<xref rid="pone.0171124.ref033" ref-type="bibr">33</xref>].</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>Uganda</bold></td><td align="justify" rowspan="1" colspan="1">Entebbe</td><td align="center" rowspan="1" colspan="1">19.2</td><td align="center" rowspan="1" colspan="1">2006/09</td><td align="justify" rowspan="1" colspan="1">Incident cases: Persons that seroconverted during 1- or 3-month. Persons (including women in antenatal care) not followed in the HIV incidence studies but had documentations of a previous HIV-negative test results were also eligible. HIV recency defined by a positive antibody test with a negative antibody test in the past 1 year, or an indeterminate/negative antibody test with detectable HIV RNA or p24 antigen) [<xref rid="pone.0171124.ref010" ref-type="bibr">10</xref>].</td></tr><tr><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1"><bold>Uganda</bold></td><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1">Mbarara</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">3.0</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">2005/10</td><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1">HIV-infected persons from a HIV RNA monitoring study. No history of ARV use by self-report [<xref rid="pone.0171124.ref029" ref-type="bibr">29</xref>].</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>Uganda</bold></td><td align="justify" rowspan="1" colspan="1">Southwestern Uganda</td><td align="center" rowspan="1" colspan="1">1.4</td><td align="center" rowspan="1" colspan="1">2004/10</td><td align="justify" rowspan="1" colspan="1">Incident cases: Persons that seroconverted during 3-month follow-up for 6 years and their CD4 cell count results were available. Estimated date of seroconversion was the midpoint between the last seronegative (antibody-negative test result) date and the first seropositive (antibody-positive test result) date [<xref rid="pone.0171124.ref031" ref-type="bibr">31</xref>].</td></tr><tr><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1"><bold>Uganda</bold></td><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1">Kampala</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">8.6</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">2009/10</td><td align="justify" style="background-color:#C0C0C0" rowspan="1" colspan="1">Newly diagnosed persons aged 18&#x02013;25 years voluntary counseling and testing centers, or laboratory evidence of HIV recency (defined by a positive antibody test with a negative antibody test in the past 1 year, or an indeterminate/negative antibody test with detectable HIV RNA or p24 antigen) [<xref rid="pone.0171124.ref011" ref-type="bibr">11</xref>].</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold>Uganda</bold></td><td align="justify" rowspan="1" colspan="1">Masaka, Wakiso, Mukono</td><td align="center" rowspan="1" colspan="1">6.4</td><td align="center" rowspan="1" colspan="1">2009/11</td><td align="justify" rowspan="1" colspan="1">Incident cases: Persons with high-risk behaviour who seroconverted during 6-month follow-up for 2 years. Estimated date of seroconversion was the midpoint between the last seronegative date and the first seropositive date [<xref rid="pone.0171124.ref030" ref-type="bibr">30</xref>].</td></tr></tbody></table></alternatives></table-wrap><p>Except for Entebbe and Mombasa (current updates), the observed TDR was relatively higher than those of selected regions within East Africa, published over the last decade [<xref rid="pone.0171124.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0171124.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0171124.ref026" ref-type="bibr">26</xref>&#x02013;<xref rid="pone.0171124.ref032" ref-type="bibr">32</xref>]. All the class-specific TDRMs were higher than those reported in rural parts of East Africa [<xref rid="pone.0171124.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0171124.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0171124.ref031" ref-type="bibr">31</xref>]. Whereas only NRTI TDRM was the highest when compared with TDR data in Mombasa [<xref rid="pone.0171124.ref026" ref-type="bibr">26</xref>], the contrast was true when compared with Kampala [<xref rid="pone.0171124.ref029" ref-type="bibr">29</xref>].</p></sec><sec id="sec013"><title>Clinical significance of observed TDRMs</title><p>According to the Stanford HIVdb v7.0, predicted resistance to the first-line drugs among the patients with TDR was 75% intermediate- to high-level resistance to efavirenz and nevirapine (recommended first-line NNRTI drugs), 25% to the cytosine analogues; lamivudine and emtricitabine and about 13% to tenofovir, abacavir, stavudine and didanosine (recommended NRTI drugs), and rilpivirine and etravirine (NNRTI drugs). None of the patients had intermediate- to high-level resistance to zidovudine or PI drugs (<xref rid="pone.0171124.t003" ref-type="table">Table 3</xref> and <xref ref-type="fig" rid="pone.0171124.g001">Fig 1</xref>).</p><fig id="pone.0171124.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0171124.g001</object-id><label>Fig 1</label><caption><title>Predicted antiretroviral (ARV) drug responses of eight persons with TDR mutations.</title><p>Drug responses were based on the Stanford HIVdb v7.0 report. The y-axis indicates the percentage number of sequences with TDR while the x-axis indicates the different ARV drug classes that were affected by the TDR mutations. Drugs that were unaffected by any particular TDR were excluded from the analyses. TDR&#x02014;Transmitted Drug Resistance; PIs&#x02014;Protease Inhibitors; NRTIs&#x02014;Nucleoside Reverse Transcriptase Inhibitors; NNRTIs&#x02014;Non-Nucleoside Reverse Transcriptase Inhibitors; ATV/r&#x02014;Boosted Atazanavir; FPV/r&#x02014;Boosted Fosamprenavir; IDV/r&#x02014;Boosted Indinavir; LPV/r&#x02014;Boosted Lopinavir; NFV&#x02014;Nelfinavir; TPV/r&#x02014;Boosted Tipranavir; r&#x02014;Ritonavir; 3TC&#x02014;Lamivudine; ABC&#x02014;Abacavir; AZT&#x02014;Zidovudine; D4T&#x02014;Stavudine; DDI&#x02014;Didanosine; FTC&#x02014;Emtricitabine; TDF&#x02014;Tenofovir; EFV&#x02014;Efavirenz; ETR&#x02014;Etravirine; NVP&#x02014;Nevirapine; RPV&#x02014;Rilpivirine.</p></caption><graphic xlink:href="pone.0171124.g001"/></fig><table-wrap id="pone.0171124.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0171124.t003</object-id><label>Table 3</label><caption><title>ARV drug resistance levels among persons with TDR.</title></caption><alternatives><graphic id="pone.0171124.t003g" xlink:href="pone.0171124.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Patient ID</th><th align="center" rowspan="2" colspan="1">TDR Mutation(s)</th><th align="center" rowspan="2" colspan="1">Other Non-Polymorphism(s)</th><th align="center" colspan="3" rowspan="1">Drugs Affected: Stanford HIVdb Drug Interpretation</th></tr><tr><th align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">PIs</th><th align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">NRTIs</th><th align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">NNRTIs</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><bold>0210801</bold></td><td align="center" rowspan="1" colspan="1">M184V, G190A</td><td align="center" rowspan="1" colspan="1">K101H</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">DDI<xref ref-type="table-fn" rid="t003fn002"><sup>a</sup></xref>, ABC<xref ref-type="table-fn" rid="t003fn003"><sup>b</sup></xref>, 3TC<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref>, FTC<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref></td><td align="left" rowspan="1" colspan="1">EFV<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref>, ETR<xref ref-type="table-fn" rid="t003fn003"><sup>b</sup></xref>, NVP<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref>, RPV<xref ref-type="table-fn" rid="t003fn003"><sup>b</sup></xref></td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><bold>0301602</bold></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">K103N</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">-</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">-</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">-</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">EFV<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref>, NVP<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>0631702</bold></td><td align="center" rowspan="1" colspan="1">M46IL</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">ATV/r<xref ref-type="table-fn" rid="t003fn002"><sup>a</sup></xref>, FPV/r<xref ref-type="table-fn" rid="t003fn002"><sup>a</sup></xref>, IDV/r<xref ref-type="table-fn" rid="t003fn002"><sup>a</sup></xref>, LPV/r<xref ref-type="table-fn" rid="t003fn002"><sup>a</sup></xref>, TPV<xref ref-type="table-fn" rid="t003fn002"><sup>a</sup></xref>, NVP<xref ref-type="table-fn" rid="t003fn003"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><bold>0921502</bold></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">K103N</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">V11I</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">-</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">-</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">EFV<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref>, NVP<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>1170802</bold></td><td align="center" rowspan="1" colspan="1">K65R, M184V, K103S, V106M</td><td align="center" rowspan="1" colspan="1">L10IL, A62V</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">D4T<xref ref-type="table-fn" rid="t003fn004"><sup>c</sup></xref>, 3TC<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref>, ABC<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref>, DDI<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref>, FTC<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref>, TDF<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref></td><td align="center" rowspan="1" colspan="1">EFV<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref>, NVP<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref></td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><bold>1201401</bold></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">K103N</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">-</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">-</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">-</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">EFV<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref>, NVP<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>1211302</bold></td><td align="center" rowspan="1" colspan="1">L210W</td><td align="center" rowspan="1" colspan="1">E138A</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">ABC<xref ref-type="table-fn" rid="t003fn002"><sup>a</sup></xref>, TDF<xref ref-type="table-fn" rid="t003fn002"><sup>a</sup></xref>, DDI<xref ref-type="table-fn" rid="t003fn002"><sup>a</sup></xref>, AZT<xref ref-type="table-fn" rid="t003fn003"><sup>b</sup></xref>, D4T<xref ref-type="table-fn" rid="t003fn003"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1">ETR<xref ref-type="table-fn" rid="t003fn002"><sup>a</sup></xref>, RPV<xref ref-type="table-fn" rid="t003fn003"><sup>b</sup></xref></td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><bold>1311802</bold></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">Y181C, K219N</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">V75I, V90I</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">-</td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">ABC<xref ref-type="table-fn" rid="t003fn002"><sup>a</sup></xref>, DDI<xref ref-type="table-fn" rid="t003fn002"><sup>a</sup></xref>, TDF<xref ref-type="table-fn" rid="t003fn002"><sup>a</sup></xref>, AZT<xref ref-type="table-fn" rid="t003fn003"><sup>b</sup></xref>, D4T<xref ref-type="table-fn" rid="t003fn003"><sup>b</sup></xref></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1">EFV<xref ref-type="table-fn" rid="t003fn004"><sup>c</sup></xref>, ETR<xref ref-type="table-fn" rid="t003fn004"><sup>c</sup></xref>, RPV<xref ref-type="table-fn" rid="t003fn004"><sup>c</sup></xref>, NVP<xref ref-type="table-fn" rid="t003fn005"><sup>d</sup></xref></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>PI&#x02014;Protease Inhibitors; NRTIs&#x02014;Nucleoside Reverse Transcriptase Inhibitors; NNRTIs&#x02014;Non-Nucleoside Reverse Transcriptase Inhibitors; ATV/r&#x02014;Boosted Atazanavir; FPV/r&#x02014;Boosted Fosamprenavir; IDV/r&#x02014;Boosted Indinavir; LPV/r&#x02014;Boosted Lopinavir; NFV&#x02014;Nelfinavir; TPV/r&#x02014;Boosted Tipranavir; r&#x02014;Ritonavir; 3TC&#x02014;Lamivudine; ABC&#x02014;Abacavir; AZT&#x02014;Zidovudine; D4T&#x02014;Stavudine; DDI&#x02014;Didanosine; FTC&#x02014;Emtricitabine; TDF&#x02014;Tenofovir; EFV&#x02014;Efavirenz; ETR&#x02014;Etravirine; NVP&#x02014;Nevirapine; RPV&#x02013;Rilpivirine.</p></fn><fn id="t003fn002"><p>a = Potential low-level resistance (mutation net drug score (10&#x02013;14).</p></fn><fn id="t003fn003"><p>b = Low-level resistance (mutation net drug score of 15&#x02013;30).</p></fn><fn id="t003fn004"><p>c = Intermediate resistance (mutation net drug score of 31&#x02013;59).</p></fn><fn id="t003fn005"><p>d = High-level resistance (mutation net drug score of &#x02265; 60).</p></fn><fn id="t003fn006"><p>Hyphen (-) denotes that none of the ARV drugs was affected.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec014"><title>HIV genetic diversity</title><p>HIV-1 subtype was inferred from the consensus evolutionary tree (<xref ref-type="supplementary-material" rid="pone.0171124.s001">S1 Fig</xref>). The subtype distribution was heterogeneous with subtype A predominating (n = 50, 57.5%) (<xref ref-type="fig" rid="pone.0171124.g002">Fig 2</xref>). Other HIV-1 variants included C (n = 6, 6.9%), D (n = 19, 21.8%), G (n = 2, 2.3%), and Circulating Recombinant Forms (CRFs: n = 10, 11.5%) that comprised AD (n = 8, 9.2%) and A2D (n = 2, 2.3%).</p><fig id="pone.0171124.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0171124.g002</object-id><label>Fig 2</label><caption><title>Summary of the subtyping and intersubtyping results of the phylogenetic analyses represented by pie chart.</title></caption><graphic xlink:href="pone.0171124.g002"/></fig></sec><sec id="sec015"><title>Nucleotide sequence accession numbers</title><p>All the 87 raw HIV-1 <italic>pol</italic> sequences reported in this article were deposited in the National Center for Biotechnology Information GenBank (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/genbank/">https://www.ncbi.nlm.nih.gov/genbank/</ext-link>) and curated. Their accession numbers are KX790964 to KX791050.</p></sec><sec id="sec016"><title>Factors associated with TDR</title><p>Only CD4 cell count was associated with the occurrence of TDR (p = 0.0145). Persons with TDR had a much lower CD4 median (cells/&#x003bc;L): 332 (IQR = 161.5&#x02013;540.0) versus 589 (IQR = 420.5&#x02013;726.0). No associations existed between TDR distribution and gender (p = 0.6750), participant&#x02019;s age (p = 0.3068), acute vs recent HIV-1 infection (p = 1.0000), HIV-1 subtype (A: p = 1.0000, C: p = 0.4496, D: p = 1.0000, G: p = 1.0000, AD: p = 0.5535, A2D: p = 1.0000), and viral load (p = 0.8982).</p></sec></sec><sec sec-type="conclusions" id="sec017"><title>Discussion</title><p>We report the existence of a moderate level TDR in rural western Kenya, a level higher than the estimated prevalence (7.4%) in East Africa [<xref rid="pone.0171124.ref007" ref-type="bibr">7</xref>] and the overall weighted TDR prevalence (5.6%) in the high HIV prevalence sSA [<xref rid="pone.0171124.ref027" ref-type="bibr">27</xref>]. Global TDR estimates range from 8&#x02013;22% [<xref rid="pone.0171124.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pone.0171124.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0171124.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0171124.ref046" ref-type="bibr">46</xref>]. The few independent studies in Kenya and East Africa have cited TDR prevalence of between 1&#x02013;13% [<xref rid="pone.0171124.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0171124.ref026" ref-type="bibr">26</xref>,<xref rid="pone.0171124.ref027" ref-type="bibr">27</xref>,<xref rid="pone.0171124.ref032" ref-type="bibr">32</xref>] and 0&#x02013;19%, respectively [<xref rid="pone.0171124.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0171124.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0171124.ref027" ref-type="bibr">27</xref>&#x02013;<xref rid="pone.0171124.ref031" ref-type="bibr">31</xref>,<xref rid="pone.0171124.ref033" ref-type="bibr">33</xref>]. Our results herein, including TDR prevalence, reflect information and activities as of 2012. Wide-scale and long duration of ARV use in this region could have contributed to the observed TDR prevalence [<xref rid="pone.0171124.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0171124.ref006" ref-type="bibr">6</xref>]. Current ARV coverage among adults in this region is high, estimated at 50&#x02013;69% [<xref rid="pone.0171124.ref037" ref-type="bibr">37</xref>] having been available for about nine years. Due to lack of temporal data especially after ARV scale-up [<xref rid="pone.0171124.ref010" ref-type="bibr">10</xref>], it remains unknown whether the 9.2% represents an increased TDR in this region. Published surveys have reported increasing TDR prevalence in Mombasa coastal Kenya: from 4.9% (2007/09) [<xref rid="pone.0171124.ref027" ref-type="bibr">27</xref>] to 13.2% (2009/10) [<xref rid="pone.0171124.ref026" ref-type="bibr">26</xref>]; Kampala central Uganda: from 7.0% (2002/04) [<xref rid="pone.0171124.ref011" ref-type="bibr">11</xref>] to 8.6% (2009/10) [<xref rid="pone.0171124.ref029" ref-type="bibr">29</xref>]; and Entebbe central Uganda: from 0.0% (2006/07) [<xref rid="pone.0171124.ref033" ref-type="bibr">33</xref>] to 19.2% (2006/09) [<xref rid="pone.0171124.ref010" ref-type="bibr">10</xref>], and decreasing TDR prevalence in Nairobi central Kenya: from 7.5% (2005) [<xref rid="pone.0171124.ref032" ref-type="bibr">32</xref>] to 4.5% (2007/09) [<xref rid="pone.0171124.ref027" ref-type="bibr">27</xref>]. The observed moderate TDR level in Ndhiwa is challenging to ART program due to increased risk of virological failure associated with pre-treatment drug resistance (PDR) [<xref rid="pone.0171124.ref024" ref-type="bibr">24</xref>]. The Stanford HIVdb revealed that about 9 of every 100 persons with AHI/RHI in Ndhiwa have viruses with mutations that confer at least potential low-level resistance to at least one of the ARV drug classes. Moreover, this together with the observed TDR have epidemiological consequences for further transmissions [<xref rid="pone.0171124.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0171124.ref022" ref-type="bibr">22</xref>] owing to the high HIV incidence in this region [<xref rid="pone.0171124.ref038" ref-type="bibr">38</xref>].</p><p>Compared to other regions in sSA, the rates of TDR in East Africa have been shown to be increasing, with a projected annual increase of 29% since ART rollout [<xref rid="pone.0171124.ref007" ref-type="bibr">7</xref>]. Comparatively, the findings of this study showed a moderate level of TDR that was higher than that reported from most of the regions in East Africa [<xref rid="pone.0171124.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0171124.ref027" ref-type="bibr">27</xref>&#x02013;<xref rid="pone.0171124.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0171124.ref031" ref-type="bibr">31</xref>&#x02013;<xref rid="pone.0171124.ref033" ref-type="bibr">33</xref>] especially in studies from rural settings [<xref rid="pone.0171124.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0171124.ref028" ref-type="bibr">28</xref>&#x02013;<xref rid="pone.0171124.ref031" ref-type="bibr">31</xref>]. This can partly be explained by the high prevalence and incidence in the study region as well as the more accurate means for assessing incidence [<xref rid="pone.0171124.ref037" ref-type="bibr">37</xref>]. Among the studies compared, majority assessed TDR among persons initiating ART with unknown time of infection. Studies have shown possible archiving of TDR mutations due to comparatively higher viral fitness of the wild-type strains and it is likely that these studies may have underestimated the TDR levels as confounded by the choice of population studied [<xref rid="pone.0171124.ref047" ref-type="bibr">47</xref>]. The observed TDR in Ndhiwa was however lower than that observed in the urban settings of Mombasa (13.2%) and Entebbe (19.2%). The difference in this may be explained by the difference in the epidemic in the two regions. For example, in Mombasa HIV transmission occurs substantially through injection drug use (IDU) [<xref rid="pone.0171124.ref048" ref-type="bibr">48</xref>] while that in Ndhiwa it is mainly heterosexual. IDU has been associated with a higher risk of primary HIV transmission in many parts of the world [<xref rid="pone.0171124.ref049" ref-type="bibr">49</xref>]. On the other hand, ART rollout in Uganda and Kenya started in 2000 and 2003, respectively [<xref rid="pone.0171124.ref027" ref-type="bibr">27</xref>]. Thus, the length of ART use in Uganda is higher than that of Ndhiwa, which may partly explain the nearly 2 times TDR difference observed in the two regions, i.e., 19.2% in Entebbe (Uganda) against 9.2% in Ndhiwa [<xref rid="pone.0171124.ref027" ref-type="bibr">27</xref>].</p><p>As reported from other studies, NNRTI mutations comprised a majority of the detected TDRMs [<xref rid="pone.0171124.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0171124.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0171124.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0171124.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="pone.0171124.ref027" ref-type="bibr">27</xref>,<xref rid="pone.0171124.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0171124.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0171124.ref032" ref-type="bibr">32</xref>], with K103N/S predominating. The high occurrence of this mutation is due to its ease of transmission compared with PI- and NRTI-associated TDRMs [<xref rid="pone.0171124.ref050" ref-type="bibr">50</xref>] and the tendency to persist for long durations [<xref rid="pone.0171124.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0171124.ref051" ref-type="bibr">51</xref>]. Moreover, the observed high level could be due to the previous use of nevirapine monotherapy or nevirapine tail in short-course triple ART PMTCT, which has been associated with increased risk of resistance [<xref rid="pone.0171124.ref037" ref-type="bibr">37</xref>,<xref rid="pone.0171124.ref052" ref-type="bibr">52</xref>]. Contrary to other studies in East Africa, we also observed a high frequency of M184V mutation [<xref rid="pone.0171124.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0171124.ref026" ref-type="bibr">26</xref>,<xref rid="pone.0171124.ref028" ref-type="bibr">28</xref>,<xref rid="pone.0171124.ref030" ref-type="bibr">30</xref>&#x02013;<xref rid="pone.0171124.ref032" ref-type="bibr">32</xref>]. The levels of observed NRTI mutations may suggest a change from the predominantly NNRTI to a combined RTI TDR epidemic, with majority of NRTI being M184V mutation. M184V is however generally highly revertant. Although studies have suggested a low fitness and hence transmission of M184V mutation, studies using more sensitive genotyping assays have shown that this mutation may still be transmitted [<xref rid="pone.0171124.ref053" ref-type="bibr">53</xref>] as minority variants. However, it is also likely that the observed mutations may be transmitted from patients on treatment who received non-standardized regimen or those failing treatment with resistance strains. Limited information exists pertaining acquired drug resistance from this population. Thus, more studies may be needed to verify whether the HIV TDR variants that we identified were transmitted from persons on HAART.</p><p>Phylogenetic analyses revealed that among persons with AHI/RHI, HIV-1 subtype A prevailed as the most frequent strain in circulation. HIV-1 subtypes C and G, and each of the variants of intersubtype recombinant mosaics (AD and A2D) were marginally present. Cumulatively, the frequency of CRFs was high. Some recombinants might indicate multiple infections [<xref rid="pone.0171124.ref054" ref-type="bibr">54</xref>] or independent transmission networks [<xref rid="pone.0171124.ref055" ref-type="bibr">55</xref>], but further analyses are essential to validate these. Consistent with previous molecular epidemiological assessments, we found subtypes A and D to be the most predominant strains that drive the epidemics in Kenya [<xref rid="pone.0171124.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0171124.ref026" ref-type="bibr">26</xref>,<xref rid="pone.0171124.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0171124.ref056" ref-type="bibr">56</xref>] and East Africa [<xref rid="pone.0171124.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0171124.ref028" ref-type="bibr">28</xref>&#x02013;<xref rid="pone.0171124.ref031" ref-type="bibr">31</xref>,<xref rid="pone.0171124.ref033" ref-type="bibr">33</xref>]. Intersubtype AD remained the most common HIV-1 recombinant [<xref rid="pone.0171124.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0171124.ref031" ref-type="bibr">31</xref>,<xref rid="pone.0171124.ref033" ref-type="bibr">33</xref>]. Great HIV diversity can foil accurate diagnosis, effective treatment and vaccine design [<xref rid="pone.0171124.ref057" ref-type="bibr">57</xref>].</p><p>Low CD4 cell count was significantly associated with TDR, a plausible indication of a rapid disease progression associated with drug-resistant strains. TDR has been shown to have a profound impact on HIV-1 pathogenesis in recently infected individuals. Individuals infected with HIV-1 strains with TDR have a rapid depletion of CD4 cell count during the first year of infection [<xref rid="pone.0171124.ref058" ref-type="bibr">58</xref>]. The associations of TDR distribution with other variables were not statistically significant. Though one study reported an association between TDR prevalence and AHI (mean seroconversion period: 45 days) [<xref rid="pone.0171124.ref012" ref-type="bibr">12</xref>], in our study, we found no association of TDR with the AHI/RHI period. The absence of TDR mutations in persons with AHI in our survey could have resulted from missed minority-level archived mutations by DBS genotyping [<xref rid="pone.0171124.ref059" ref-type="bibr">59</xref>].</p><p>Shortcomings of the study included potential for misclassification (bias) associated with the serological assays for characterizing the age of infection. Thus, there is chance that a few chronic infections might have been misclassified as RHI. To minimize this, we used recent infection testing algorithm (RITA), based on two serological assays and surrogate markers to provide information on recency [<xref rid="pone.0171124.ref018" ref-type="bibr">18</xref>]. The two serological assays that we used have been observed to have a low false positive rate (FPR) in this population; BioRad (2.4) and LAg avidity (0.5%) [<xref rid="pone.0171124.ref060" ref-type="bibr">60</xref>]. This variation can be due to influence by HIV-1 subtype [<xref rid="pone.0171124.ref061" ref-type="bibr">61</xref>]. The low FPR (&#x0003c;2%) of LAg avidity was consistent with the characteristics of an acceptable assay [<xref rid="pone.0171124.ref035" ref-type="bibr">35</xref>]. Because RITA cannot eliminate all FPR, viral load measurements were included to reduce the FPR [<xref rid="pone.0171124.ref018" ref-type="bibr">18</xref>]. As compared to massive parallel sequencing, the population-based sequencing might have not detected &#x0201c;sentinel mutations&#x0201d; in quasispecies, thus, possibly underestimating the TDR in this population [<xref rid="pone.0171124.ref004" ref-type="bibr">4</xref>,<xref rid="pone.0171124.ref062" ref-type="bibr">62</xref>&#x02013;<xref rid="pone.0171124.ref064" ref-type="bibr">64</xref>].</p></sec><sec sec-type="conclusions" id="sec018"><title>Conclusions</title><p>Despite these limitations, we reveal the presence of a relatively higher TDR prevalence in rural western Kenya than in most regions within East Africa. We propose that the WHO-recommended programmatic actions for moderate TDR level be performed, including evaluation of early warning indicators and both regional and nationwide PDR survey to determine the causes of TDR and advise on choice of first-line treatment in case of persistent high-level PDR [<xref rid="pone.0171124.ref034" ref-type="bibr">34</xref>].</p></sec><sec sec-type="supplementary-material" id="sec019"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0171124.s001"><label>S1 Fig</label><caption><title>MEGA phylogenetic maximum likelihood (ML) circular tree for HIV-1 subtyping of the partial <italic>pol</italic> gene from AHI/RHI antiretroviral-na&#x000ef;ve persons in the Ndhiwa cohort.</title><p>The evolutionary history was inferred from bootstrap phylogeny test (1000 replicates) using ML phylogenetic reconstruction based on Hasegawa-Kishino-Yano with Gamma distribution and Invariable sites (HKY+G+I) model. The tree was rooted on HIV-1 subtype K (marked with &#x025cf;). The 19 reference sequences used are marked with &#x025bc; beside their names. The clustering of the 87 viral sequences with respect to the reference sequences allowed for the identity of the associated taxa.</p><p>(TIF)</p></caption><media xlink:href="pone.0171124.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We greatly express our appreciation to all the study participants. We acknowledge the efforts of the MSF staff in the field, technical support accorded to us by NASCOP, KEMRI/CDC HIV-Research laboratory team. This work was funded by the M&#x000e9;decins Sans Fronti&#x000e8;res (MSF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p><sec id="sec020"><title>Disclaimer</title><p>The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the U.S. Centers for Disease Control and Prevention. Use of trade names is for identification purposes only and does not constitute endorsement by the U.S. Centers for Disease Control and Prevention or the Department of Health and Human Services.</p></sec></ack><ref-list><title>References</title><ref id="pone.0171124.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Clavel</surname><given-names>F</given-names></name>, <name><surname>Hance</surname><given-names>AJ</given-names></name>. <article-title>HIV Drug Resistance</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>350</volume>(<issue>10</issue>):<fpage>1023</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra025195</pub-id>
<?supplied-pmid 14999114?><pub-id pub-id-type="pmid">14999114</pub-id></mixed-citation></ref><ref id="pone.0171124.ref002"><label>2</label><mixed-citation publication-type="other">UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. 2013.</mixed-citation></ref><ref id="pone.0171124.ref003"><label>3</label><mixed-citation publication-type="other">NASCOP. Kenya AIDS Indicator Survey 2012: Preliminary Report. 2013.</mixed-citation></ref><ref id="pone.0171124.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Chan</surname><given-names>PA</given-names></name>, <name><surname>Kantor</surname><given-names>R</given-names></name>. <article-title>Transmitted Drug Resistance in Nonsubtype B HIV-1 Infection</article-title>. <source>HIV Ther</source>. <year>2009</year>;<volume>3</volume>(<issue>5</issue>):<fpage>447</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.2217/hiv.09.30</pub-id>
<?supplied-pmid 20161523?><pub-id pub-id-type="pmid">20161523</pub-id></mixed-citation></ref><ref id="pone.0171124.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Hamers</surname><given-names>RL</given-names></name>, <name><surname>Sigaloff</surname><given-names>KCE</given-names></name>, <name><surname>Kityo</surname><given-names>C</given-names></name>, <name><surname>Mugyenyi</surname><given-names>P</given-names></name>, <name><surname>de Wit</surname><given-names>TFR</given-names></name>. <article-title>Emerging HIV-1 Drug Resistance after Roll-out of Antiretroviral Therapy in sub-Saharan Africa</article-title>. <source>Curr Opin HIV AIDS</source>. <year>2013</year>;<volume>8</volume>(<issue>1</issue>):<fpage>19</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1097/COH.0b013e32835b7f94</pub-id>
<?supplied-pmid 23143140?><pub-id pub-id-type="pmid">23143140</pub-id></mixed-citation></ref><ref id="pone.0171124.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Aghokeng</surname><given-names>AF</given-names></name>, <name><surname>Kouanfack</surname><given-names>C</given-names></name>, <name><surname>Laurent</surname><given-names>C</given-names></name>, <name><surname>Ebong</surname><given-names>E</given-names></name>, <name><surname>Atem-Tambe</surname><given-names>A</given-names></name>, <name><surname>Butel</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Scale-up of Antiretroviral Treatment in sub-Saharan Africa is Accompanied by Increasing HIV-1 Drug Resistance Mutations in Drug-Na&#x000ef;ve Patients</article-title>. <source>AIDS</source>. <year>2011</year>;<volume>25</volume>(<issue>17</issue>):<fpage>2183</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e32834bbbe9</pub-id>
<?supplied-pmid 21860346?><pub-id pub-id-type="pmid">21860346</pub-id></mixed-citation></ref><ref id="pone.0171124.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Gupta</surname><given-names>RK</given-names></name>, <name><surname>Jordan</surname><given-names>MR</given-names></name>, <name><surname>Sultan</surname><given-names>BJ</given-names></name>, <name><surname>Hill</surname><given-names>A</given-names></name>, <name><surname>Davis</surname><given-names>DHJ</given-names></name>, <name><surname>Gregson</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Global Trends in Antiretroviral Resistance in Treatment-Na&#x000ef;ve Individuals with HIV after Rollout of Antiretroviral Treatment in Resource-Limited Settings: A Global Collaborative Study and Meta-Regression Analysis</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>380</volume>(<issue>9849</issue>):<fpage>1250</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(12)61038-1</pub-id>
<?supplied-pmid 22828485?><pub-id pub-id-type="pmid">22828485</pub-id></mixed-citation></ref><ref id="pone.0171124.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Jain</surname><given-names>V</given-names></name>, <name><surname>Liegler</surname><given-names>T</given-names></name>, <name><surname>Vittinghoff</surname><given-names>E</given-names></name>, <name><surname>Hartogensis</surname><given-names>W</given-names></name>, <name><surname>Bacchetti</surname><given-names>P</given-names></name>, <name><surname>Poole</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Transmitted Drug Resistance in Persons with Acute/Early HIV-1 in San Francisco, 2002&#x02013;2009</article-title>. <source>PLoS One</source>. <year>2010</year>;<volume>5</volume>(<issue>12</issue>):<fpage>e15510</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0015510</pub-id>
<?supplied-pmid 21170322?><pub-id pub-id-type="pmid">21170322</pub-id></mixed-citation></ref><ref id="pone.0171124.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Skoura</surname><given-names>L</given-names></name>, <name><surname>Metallidis</surname><given-names>S</given-names></name>, <name><surname>Pilalas</surname><given-names>D</given-names></name>, <name><surname>Kourelis</surname><given-names>A</given-names></name>, <name><surname>Margariti</surname><given-names>A</given-names></name>, <name><surname>Papadimitriou</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>High Rates of Transmitted Drug Resistance among Newly-Diagnosed Antiretroviral Na&#x000ef;ve HIV Patients in Northern Greece, Data from 2009&#x02013;2011</article-title>. <source>Clin Microbiol Infect</source>. <year>2013</year>;<volume>19</volume>:<fpage>E169</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1111/1469-0691.12124</pub-id>
<?supplied-pmid 23331664?><pub-id pub-id-type="pmid">23331664</pub-id></mixed-citation></ref><ref id="pone.0171124.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Price</surname><given-names>MA</given-names></name>, <name><surname>Wallis</surname><given-names>CL</given-names></name>, <name><surname>Lakhi</surname><given-names>S</given-names></name>, <name><surname>Karita</surname><given-names>E</given-names></name>, <name><surname>Kamali</surname><given-names>A</given-names></name>, <name><surname>Anzala</surname><given-names>O</given-names></name>, <etal>et al</etal>
<article-title>Transmitted HIV Type 1 Drug Resistance among Individuals with Recent HIV Infection in East and Southern Africa</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2011</year>;<volume>27</volume>(<issue>1</issue>):<fpage>5</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1089/aid.2010.0030</pub-id>
<?supplied-pmid 21091377?><pub-id pub-id-type="pmid">21091377</pub-id></mixed-citation></ref><ref id="pone.0171124.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Ndembi</surname><given-names>N</given-names></name>, <name><surname>Hamers</surname><given-names>RL</given-names></name>, <name><surname>Sigaloff</surname><given-names>KCE</given-names></name>, <name><surname>Lyagoba</surname><given-names>F</given-names></name>, <name><surname>Magambo</surname><given-names>B</given-names></name>, <name><surname>Nanteza</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Transmitted Antiretroviral Drug Resistance among Newly HIV-1 Diagnosed Young Individuals in Kampala</article-title>. <source>AIDS</source>. <year>2011</year>;<volume>25</volume>(<issue>7</issue>):<fpage>905</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e328346260f</pub-id>
<?supplied-pmid 21399479?><pub-id pub-id-type="pmid">21399479</pub-id></mixed-citation></ref><ref id="pone.0171124.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Yanik</surname><given-names>EL</given-names></name>, <name><surname>Napravnik</surname><given-names>S</given-names></name>, <name><surname>Hurt</surname><given-names>CB</given-names></name>, <name><surname>Dennis</surname><given-names>A</given-names></name>, <name><surname>Quinlivan</surname><given-names>EB</given-names></name>, <name><surname>Sebastian</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Prevalence of Transmitted Antiretroviral Drug Resistance Differs between Acutely and Chronically HIV-Infected Patients</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2012</year>;<volume>61</volume>(<issue>2</issue>):<fpage>258</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0b013e3182618f05</pub-id>
<?supplied-pmid 22692092?><pub-id pub-id-type="pmid">22692092</pub-id></mixed-citation></ref><ref id="pone.0171124.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Hurt</surname><given-names>CB</given-names></name>, <name><surname>Mccoy</surname><given-names>SI</given-names></name>, <name><surname>Kuruc</surname><given-names>J</given-names></name>, <name><surname>Kerkau</surname><given-names>M</given-names></name>, <name><surname>Fiscus</surname><given-names>S</given-names></name>, <name><surname>Mcgee</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Transmitted Antiretroviral Drug Resistance among Acute and Recent HIV Infections in North Carolina, 1998 to 2007</article-title>. <source>Antivir Ther</source>. <year>2010</year>;<volume>14</volume>(<issue>5</issue>):<fpage>673</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="pone.0171124.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Jakobsen</surname><given-names>MR</given-names></name>, <name><surname>Tolstrup</surname><given-names>M</given-names></name>, <name><surname>S&#x000f8;gaard</surname><given-names>OS</given-names></name>, <name><surname>J&#x000f8;rgensen</surname><given-names>LB</given-names></name>, <name><surname>Gorry</surname><given-names>PR</given-names></name>, <name><surname>Laursen</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Transmission of HIV-1 Drug-Resistant Variants: Prevalence and Effect on Treatment Outcome</article-title>. <source>Clin Infect Dis</source>. <year>2010</year>;<volume>50</volume>(<issue>4</issue>):<fpage>566</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1086/650001</pub-id>
<?supplied-pmid 20085464?><pub-id pub-id-type="pmid">20085464</pub-id></mixed-citation></ref><ref id="pone.0171124.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Deeks</surname><given-names>SG</given-names></name>. <article-title>Treatment of Antiretroviral-Drug-Resistant HIV-1 Infection</article-title>. <source>Lancet</source>. <year>2003</year>;<volume>362</volume>(<issue>9400</issue>):<fpage>2002</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)15022-2</pub-id>
<?supplied-pmid 14683662?><pub-id pub-id-type="pmid">14683662</pub-id></mixed-citation></ref><ref id="pone.0171124.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Hassan</surname><given-names>AS</given-names></name>, <name><surname>Mwaringa</surname><given-names>SM</given-names></name>, <name><surname>Obonyo</surname><given-names>CA</given-names></name>, <name><surname>Nabwera</surname><given-names>HM</given-names></name>, <name><surname>Sanders</surname><given-names>EJ</given-names></name>, <name><surname>Wit</surname><given-names>TFR De</given-names></name>, <etal>et al</etal>
<article-title>Low Prevalence of Transmitted HIV Type 1 Drug Resistance among Antiretroviral-Na&#x000ef;ve Adults in a Rural HIV Clinic in Kenya</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2013</year>;<volume>29</volume>(<issue>1</issue>):<fpage>129</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1089/AID.2012.0167</pub-id>
<?supplied-pmid 22900472?><pub-id pub-id-type="pmid">22900472</pub-id></mixed-citation></ref><ref id="pone.0171124.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Nichols</surname><given-names>BE</given-names></name>, <name><surname>Sigaloff</surname><given-names>KCE</given-names></name>, <name><surname>Kityo</surname><given-names>C</given-names></name>, <name><surname>Mandaliya</surname><given-names>K</given-names></name>, <name><surname>Hamers</surname><given-names>RL</given-names></name>, <name><surname>Bertagnolio</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Averted HIV Infections Due To Expanded Antiretroviral Treatment Eligibility Offsets Risk of Transmitted Drug Resistance: A Modeling Study</article-title>. <source>AIDS</source>. <year>2014</year>;<volume>28</volume>(<issue>1</issue>):<fpage>73</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1097/01.aids.0000433239.01611.52</pub-id>
<?supplied-pmid 23921620?><pub-id pub-id-type="pmid">23921620</pub-id></mixed-citation></ref><ref id="pone.0171124.ref018"><label>18</label><mixed-citation publication-type="other">UNAIDS/WHO. When and How to Use Assays for Recent Infection to Estimate HIV Incidence at a Population Level. 2011.</mixed-citation></ref><ref id="pone.0171124.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Hirsch</surname><given-names>MS</given-names></name>, <name><surname>Brun-V&#x000e9;zinet</surname><given-names>F</given-names></name>, <name><surname>Clotet</surname><given-names>B</given-names></name>, <name><surname>Conway</surname><given-names>B</given-names></name>, <name><surname>Kuritzkes</surname><given-names>DR</given-names></name>, <name><surname>D&#x02019;Aquila</surname><given-names>RT</given-names></name>, <etal>et al</etal>
<article-title>Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society-USA Panel</article-title>. <source>Clin Infect Dis</source>. <year>2003</year>;<volume>37</volume>(<issue>1</issue>):<fpage>113</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1086/375597</pub-id>
<?supplied-pmid 12830416?><pub-id pub-id-type="pmid">12830416</pub-id></mixed-citation></ref><ref id="pone.0171124.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Bennett</surname><given-names>DE</given-names></name>, <name><surname>Myatt</surname><given-names>M</given-names></name>, <name><surname>Bertagnolio</surname><given-names>S</given-names></name>, <name><surname>Sutherland</surname><given-names>D</given-names></name>, <name><surname>Gilks</surname><given-names>CF</given-names></name>. <article-title>Recommendations for Surveillance of Transmitted HIV Drug Resistance in Countries Scaling up Antiretroviral Treatment</article-title>. <source>Antivir Ther</source>. <year>2008</year>;<volume>13</volume>
<issue>Suppl 2</issue>:<fpage>25</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">18575189</pub-id></mixed-citation></ref><ref id="pone.0171124.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Hamers</surname><given-names>RL</given-names></name>, <name><surname>Derdelinckx</surname><given-names>I</given-names></name>, <name><surname>Stevens</surname><given-names>W</given-names></name>. <article-title>The Status of HIV-1 Resistance to Antiretroviral Drugs in sub-Saharan Africa</article-title>. <source>Antivir Ther</source>. <year>2008</year>;<volume>13</volume>:<fpage>625</fpage>&#x02013;<lpage>39</lpage>. <?supplied-pmid 18771046?><pub-id pub-id-type="pmid">18771046</pub-id></mixed-citation></ref><ref id="pone.0171124.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Cambiano</surname><given-names>V</given-names></name>, <name><surname>Bertagnolio</surname><given-names>S</given-names></name>, <name><surname>Jordan</surname><given-names>MR</given-names></name>, <name><surname>Lundgren</surname><given-names>JD</given-names></name>, <name><surname>Phillips</surname><given-names>A</given-names></name>. <article-title>Transmission of Drug Resistant HIV and its Potential Impact on Mortality and Treatment Outcomes in Resource-Limited Settings</article-title>. <source>J Infect Dis</source>. <year>2013</year>;<volume>207</volume>(<issue>Suppl 2</issue>):<fpage>S57</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">23687290</pub-id></mixed-citation></ref><ref id="pone.0171124.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Little</surname><given-names>SJJ</given-names></name>, <name><surname>Holte</surname><given-names>S</given-names></name>, <name><surname>Routy</surname><given-names>J-P</given-names></name>, <name><surname>Daar</surname><given-names>ESS</given-names></name>, <name><surname>Markowitz</surname><given-names>M</given-names></name>, <name><surname>Collier</surname><given-names>ACC</given-names></name>, <etal>et al</etal>
<article-title>Antiretroviral-Drug Resistance among Patients Recently Infected with HIV</article-title>. <source>N Engl J Med</source>. <year>2002</year>;<volume>347</volume>(<issue>6</issue>):<fpage>385</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa013552</pub-id>
<?supplied-pmid 12167680?><pub-id pub-id-type="pmid">12167680</pub-id></mixed-citation></ref><ref id="pone.0171124.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Wittkop</surname><given-names>L</given-names></name>, <name><surname>G&#x000fc;nthard</surname><given-names>HF</given-names></name>, <name><surname>de Wolf</surname><given-names>F</given-names></name>, <name><surname>Dunn</surname><given-names>D</given-names></name>, <name><surname>Cozzi-Lepri</surname><given-names>A</given-names></name>, <name><surname>de Luca</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Effect of Transmitted Drug Resistance on Virological and Immunological Response to Initial Combination Antiretroviral Therapy for HIV (EuroCoord-CHAIN Joint Project): A European Multicohort Study</article-title>. <source>Lancet Infect Dis</source>. <year>2011</year>;<volume>11</volume>(<issue>5</issue>):<fpage>363</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(11)70032-9</pub-id>
<?supplied-pmid 21354861?><pub-id pub-id-type="pmid">21354861</pub-id></mixed-citation></ref><ref id="pone.0171124.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Yebra</surname><given-names>G</given-names></name>, <name><surname>de Mulder</surname><given-names>M</given-names></name>, <name><surname>P&#x000e9;rez-El&#x000ed;as</surname><given-names>MJ</given-names></name>, <name><surname>P&#x000e9;rez-Molina</surname><given-names>JA</given-names></name>, <name><surname>Gal&#x000e1;n</surname><given-names>JC</given-names></name>, <name><surname>Llenas-Garc&#x000ed;a</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Increase of Transmitted Drug Resistance among HIV-Infected sub-Saharan Africans Residing in Spain in Contrast to the Native Population</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>(<issue>10</issue>):<fpage>e26757</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0026757</pub-id>
<?supplied-pmid 22046345?><pub-id pub-id-type="pmid">22046345</pub-id></mixed-citation></ref><ref id="pone.0171124.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Sigallof</surname><given-names>KCE</given-names></name>, <name><surname>Mandaliya</surname><given-names>K</given-names></name>, <name><surname>Hamers</surname><given-names>RL</given-names></name>, <name><surname>Otieno</surname><given-names>F</given-names></name>, <name><surname>Jao</surname><given-names>IM</given-names></name>, <name><surname>Lyagoba</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>High Prevalence of Transmitted Antiretroviral Drug Resistance among Newly HIV Type 1 Diagnosed Adults in Mombasa, Kenya</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2012</year>;<volume>27</volume>(<issue>00</issue>):<fpage>1</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="pone.0171124.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Hamers</surname><given-names>RL</given-names></name>, <name><surname>Wallis</surname><given-names>CL</given-names></name>, <name><surname>Kityo</surname><given-names>C</given-names></name>, <name><surname>Siwale</surname><given-names>M</given-names></name>, <name><surname>Mandaliya</surname><given-names>K</given-names></name>, <name><surname>Conradie</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>HIV-1 Drug Resistance in Antiretroviral-Na&#x000ef;ve Individuals in sub-Saharan Africa after Rollout of Antiretroviral Therapy: A Multicentre Observational Study</article-title>. <source>Lancet Infect Dis</source>. <year>2011</year>;<volume>11</volume>(<issue>10</issue>):<fpage>750</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(11)70149-9</pub-id>
<?supplied-pmid 21802367?><pub-id pub-id-type="pmid">21802367</pub-id></mixed-citation></ref><ref id="pone.0171124.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Somi</surname><given-names>GR</given-names></name>, <name><surname>Kibuka</surname><given-names>T</given-names></name>, <name><surname>Diallo</surname><given-names>K</given-names></name>, <name><surname>Tuhuma</surname><given-names>T</given-names></name>, <name><surname>Bennett</surname><given-names>DE</given-names></name>, <name><surname>Yang</surname><given-names>C</given-names></name>. <article-title>Surveillance of Transmitted HIV Drug Resistance among Women Attending Antenatal Clinics in Dar es Salaam, Tanzania</article-title>. <source>Antivir Ther</source>. <year>2008</year>;<volume>13</volume>
<issue>Suppl 2</issue>:<fpage>77</fpage>&#x02013;<lpage>82</lpage>.</mixed-citation></ref><ref id="pone.0171124.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>GQ</given-names></name>, <name><surname>Bangsberg</surname><given-names>DR</given-names></name>, <name><surname>Muzoora</surname><given-names>C</given-names></name>, <name><surname>Boum</surname><given-names>Y</given-names></name>, <name><surname>Oyugi</surname><given-names>JH</given-names></name>, <name><surname>Emenyonu</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Prevalence and Virologic Consequences of Transmitted HIV-1 Drug Resistance in Uganda</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2014</year>;<volume>30</volume>(<issue>9</issue>):<fpage>896</fpage>&#x02013;<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1089/AID.2014.0043</pub-id>
<?supplied-pmid 24960249?><pub-id pub-id-type="pmid">24960249</pub-id></mixed-citation></ref><ref id="pone.0171124.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Ndembi</surname><given-names>N</given-names></name>, <name><surname>Birungi</surname><given-names>J</given-names></name>, <name><surname>Lyagoba</surname><given-names>F</given-names></name>, <name><surname>Gershim</surname><given-names>A</given-names></name>, <name><surname>Nakiyingi-Miiro</surname><given-names>J</given-names></name>, <name><surname>Nielsen</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Short Communication: HIV Type 1 Transmitted Drug Resistance and Evidence Antiretroviral-Na&#x000ef;ve Individuals from Ugandan Fishing Communities of Lake Victoria</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2013</year>;<volume>29</volume>(<issue>5</issue>):<fpage>788</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1089/AID.2012.0123</pub-id>
<?supplied-pmid 23173702?><pub-id pub-id-type="pmid">23173702</pub-id></mixed-citation></ref><ref id="pone.0171124.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Ssemwanga</surname><given-names>D</given-names></name>, <name><surname>Kapaata</surname><given-names>A</given-names></name>, <name><surname>Lyagoba</surname><given-names>F</given-names></name>, <name><surname>Magambo</surname><given-names>B</given-names></name>, <name><surname>Nanyonjo</surname><given-names>M</given-names></name>, <name><surname>Mayanja</surname><given-names>BN</given-names></name>, <etal>et al</etal>
<article-title>Low Drug Resistance Levels among Drug-Naive Individuals with Recent HIV Type 1 Infection in a Rural Clinical Cohort in Southwestern Uganda</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2012</year>;<volume>28</volume>(<issue>12</issue>):<fpage>1784</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1089/AID.2012.0090</pub-id>
<?supplied-pmid 22616647?><pub-id pub-id-type="pmid">22616647</pub-id></mixed-citation></ref><ref id="pone.0171124.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Lihana</surname><given-names>RW</given-names></name>, <name><surname>Khamadi</surname><given-names>S a</given-names></name>, <name><surname>Lubano</surname><given-names>K</given-names></name>, <name><surname>Lwembe</surname><given-names>R</given-names></name>, <name><surname>Kiptoo</surname><given-names>MK</given-names></name>, <name><surname>Lagat</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>HIV Type 1 Subtype Diversity and Drug Resistance among HIV Type 1-Infected Kenyan Patients Initiating Antiretroviral Therapy</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2009</year>;<volume>25</volume>(<issue>12</issue>):<fpage>1211</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1089/aid.2009.0007</pub-id>
<?supplied-pmid 19954302?><pub-id pub-id-type="pmid">19954302</pub-id></mixed-citation></ref><ref id="pone.0171124.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Ndembi</surname><given-names>N</given-names></name>, <name><surname>Lyagoba</surname><given-names>F</given-names></name>, <name><surname>Nanteza</surname><given-names>B</given-names></name>, <name><surname>Kushemererwa</surname><given-names>G</given-names></name>, <name><surname>Serwanga</surname><given-names>J</given-names></name>, <name><surname>Katongole-Mbidde</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Transmitted Antiretroviral Drug Resistance Surveillance among Newly HIV Type 1-Diagnosed Women Attending an Antenatal Clinic in Entebbe, Uganda</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2008</year>;<volume>24</volume>(<issue>6</issue>):<fpage>889</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1089/aid.2007.0317</pub-id>
<?supplied-pmid 18544019?><pub-id pub-id-type="pmid">18544019</pub-id></mixed-citation></ref><ref id="pone.0171124.ref034"><label>34</label><mixed-citation publication-type="other">WHO. Meeting Report on Framework for Metrics to Support Effective Treatment as Prevention. 2012.</mixed-citation></ref><ref id="pone.0171124.ref035"><label>35</label><mixed-citation publication-type="journal"><collab>Incidence Assay Critical Path Working Group</collab>. <article-title>More and Better Information to Tackle HIV Epidemics: Towards Improved HIV Incidence Assays</article-title>. <source>PLoS Med</source>. <year>2011</year>;<volume>8</volume>(<issue>6</issue>):<fpage>e1001045</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pmed.1001045</pub-id>
<?supplied-pmid 21731474?><pub-id pub-id-type="pmid">21731474</pub-id></mixed-citation></ref><ref id="pone.0171124.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Hosseinipour</surname><given-names>MC</given-names></name>, <name><surname>Gupta</surname><given-names>RK</given-names></name>, <name><surname>Van Zyl</surname><given-names>G</given-names></name>, <name><surname>Eron</surname><given-names>JJ</given-names></name>, <name><surname>Nachega</surname><given-names>JB</given-names></name>. <article-title>Emergence of HIV Drug Resistance During First- and Second-Line Antiretroviral Therapy in Resource-Limited Settings</article-title>. <source>J Infect Dis</source>. <year>2013</year>;<volume>207</volume>(<issue>Suppl 2</issue>):<fpage>S49</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">23687289</pub-id></mixed-citation></ref><ref id="pone.0171124.ref037"><label>37</label><mixed-citation publication-type="other">Maman D, Masson S, Riche B. Ndhiwa HIV Impact in Population Survey. 2014.</mixed-citation></ref><ref id="pone.0171124.ref038"><label>38</label><mixed-citation publication-type="other">Ministry of Health. Kenya HIV Prevention Revolution Road Map&#x02014;Count Down To 2030. 2014.</mixed-citation></ref><ref id="pone.0171124.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>Z</given-names></name>, <name><surname>Wagar</surname><given-names>N</given-names></name>, <name><surname>DeVos</surname><given-names>JR</given-names></name>, <name><surname>Rottinghaus</surname><given-names>E</given-names></name>, <name><surname>Diallo</surname><given-names>K</given-names></name>, <name><surname>Nguyen</surname><given-names>DB</given-names></name>, <etal>et al</etal>
<article-title>Optimization of a Low Cost and Broadly Sensitive Genotyping Assay for HIV-1 Drug Resistance Surveillance and Monitoring in Resource-Limited Settings</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>(<issue>11</issue>):<fpage>e28184</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0028184</pub-id>
<?supplied-pmid 22132237?><pub-id pub-id-type="pmid">22132237</pub-id></mixed-citation></ref><ref id="pone.0171124.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Woods</surname><given-names>CK</given-names></name>, <name><surname>Brumme</surname><given-names>CJ</given-names></name>, <name><surname>Liu</surname><given-names>TF</given-names></name>, <name><surname>Chui</surname><given-names>CKS</given-names></name>, <name><surname>Chu</surname><given-names>AL</given-names></name>, <name><surname>Wynhoven</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Automating HIV Drug Resistance Genotyping with RECall, A Freely Accessible Sequence Analysis Tool</article-title>. <source>J Clin Microbiol</source>. <year>2012</year>;<volume>50</volume>(<issue>6</issue>):<fpage>1936</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.06689-11</pub-id>
<?supplied-pmid 22403431?><pub-id pub-id-type="pmid">22403431</pub-id></mixed-citation></ref><ref id="pone.0171124.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Dereeper</surname><given-names>A</given-names></name>, <name><surname>Guignon</surname><given-names>V</given-names></name>, <name><surname>Blanc</surname><given-names>G</given-names></name>, <name><surname>Audic</surname><given-names>S</given-names></name>, <name><surname>Buffet</surname><given-names>S</given-names></name>, <name><surname>Chevenet</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Phylogeny.fr: Robust Phylogenetic Analysis for the Non-Specialist</article-title>. <source>Nucleic Acids Res</source>. <year>2008</year>;<volume>36</volume>(Web Server issue):<fpage>W465</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkn180</pub-id>
<?supplied-pmid 18424797?><pub-id pub-id-type="pmid">18424797</pub-id></mixed-citation></ref><ref id="pone.0171124.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Bennett</surname><given-names>DE</given-names></name>, <name><surname>Camacho</surname><given-names>RJ</given-names></name>, <name><surname>Otelea</surname><given-names>D</given-names></name>, <name><surname>Kuritzkes</surname><given-names>DR</given-names></name>, <name><surname>Fleury</surname><given-names>H</given-names></name>, <name><surname>Kiuchi</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update</article-title>. <source>PLoS One</source>. <year>2009</year>;<volume>4</volume>(<issue>3</issue>):<fpage>e4724</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0004724</pub-id>
<?supplied-pmid 19266092?><pub-id pub-id-type="pmid">19266092</pub-id></mixed-citation></ref><ref id="pone.0171124.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Tang</surname><given-names>MW</given-names></name>, <name><surname>Liu</surname><given-names>TF</given-names></name>, <name><surname>Shafer</surname><given-names>RW</given-names></name>. <article-title>The HIVdb System for HIV-1 Genotypic Resistance Interpretation</article-title>. <source>Intervirology</source>. <year>2012</year>;<volume>5107</volume>:<fpage>98</fpage>&#x02013;<lpage>101</lpage>.</mixed-citation></ref><ref id="pone.0171124.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Tamura</surname><given-names>K</given-names></name>, <name><surname>Stecher</surname><given-names>G</given-names></name>, <name><surname>Peterson</surname><given-names>D</given-names></name>, <name><surname>Filipski</surname><given-names>A</given-names></name>, <name><surname>Kumar</surname><given-names>S</given-names></name>. <article-title>MEGA6: Molecular Evolutionary Genetics Analysis version 6.0</article-title>. <source>Mol Biol Evol</source>. <year>2013</year>;<volume>30</volume>(<issue>12</issue>):<fpage>2725</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/molbev/mst197</pub-id>
<?supplied-pmid 24132122?><pub-id pub-id-type="pmid">24132122</pub-id></mixed-citation></ref><ref id="pone.0171124.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>LD</given-names></name>, <name><surname>DasGupta</surname><given-names>A</given-names></name>, <name><surname>Cai</surname><given-names>TT</given-names></name>. <article-title>Interval Estimation for a Binomial Proportion</article-title>. <source>Stat Sci</source>. <year>2001</year>;<volume>16</volume>(<issue>2</issue>):<fpage>101</fpage>&#x02013;<lpage>33</lpage>.</mixed-citation></ref><ref id="pone.0171124.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Readhead</surname><given-names>AC</given-names></name>, <name><surname>Gordon</surname><given-names>DE</given-names></name>, <name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>Anderson</surname><given-names>BJ</given-names></name>, <name><surname>Brousseau</surname><given-names>KS</given-names></name>, <name><surname>Kouznetsova</surname><given-names>MA</given-names></name>, <etal>et al</etal>
<article-title>Transmitted Antiretroviral Drug Resistance in New York State, 2006&#x02013;2008: Results from a New Surveillance System</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>8</issue>):<fpage>e40533</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0040533</pub-id>
<?supplied-pmid 22879878?><pub-id pub-id-type="pmid">22879878</pub-id></mixed-citation></ref><ref id="pone.0171124.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Jain</surname><given-names>V</given-names></name>, <name><surname>Sucupira</surname><given-names>MC</given-names></name>, <name><surname>Bacchetti</surname><given-names>P</given-names></name>, <name><surname>Hartogensis</surname><given-names>W</given-names></name>, <name><surname>Diaz</surname><given-names>RS</given-names></name>, <name><surname>Kallas</surname><given-names>EG</given-names></name>, <etal>et al</etal>
<article-title>Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes</article-title>. <source>J Infect Dis</source>. <year>2011</year>;<volume>203</volume>(<issue>8</issue>):<fpage>1174</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiq167</pub-id>
<?supplied-pmid 21451005?><pub-id pub-id-type="pmid">21451005</pub-id></mixed-citation></ref><ref id="pone.0171124.ref048"><label>48</label><mixed-citation publication-type="book"><name><surname>Nieburg</surname><given-names>P</given-names></name>, <name><surname>Carty</surname><given-names>L</given-names></name>. <source>HIV Prevention among Injection Drug Users in Kenya and Tanzania HIV Prevention among Injection Drug Users in Kenya and Tanzania</source>. <publisher-name>CSIS</publisher-name>
<year>2011</year>.</mixed-citation></ref><ref id="pone.0171124.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Mathers</surname><given-names>BM</given-names></name>, <name><surname>Degenhardt</surname><given-names>L</given-names></name>, <name><surname>Phillips</surname><given-names>B</given-names></name>, <name><surname>Wiessing</surname><given-names>L</given-names></name>, <name><surname>Hickman</surname><given-names>M</given-names></name>, <name><surname>Strathdee</surname><given-names>S a</given-names></name>, <etal>et al</etal>
<article-title>Global Epidemiology of Injecting Drug Use and HIV among People Who Inject Drugs: A systematic Review</article-title>. <source>Lancet</source>. <year>2008</year>;<volume>372</volume>(<issue>9651</issue>):<fpage>1733</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(08)61311-2</pub-id>
<?supplied-pmid 18817968?><pub-id pub-id-type="pmid">18817968</pub-id></mixed-citation></ref><ref id="pone.0171124.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Ruelle</surname><given-names>J</given-names></name>, <name><surname>Ingels</surname><given-names>M</given-names></name>, <name><surname>Jnaoui</surname><given-names>K</given-names></name>, <name><surname>Ausselet</surname><given-names>N</given-names></name>, <name><surname>Vincent</surname><given-names>A</given-names></name>, <name><surname>Verhofstede</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Transmission Network of an HIV Type 1 Strain with K103N in Young Belgian Patients from Different Risk Groups</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2013</year>;<volume>29</volume>(<issue>10</issue>).</mixed-citation></ref><ref id="pone.0171124.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Little</surname><given-names>SJ</given-names></name>, <name><surname>Frost</surname><given-names>SDW</given-names></name>, <name><surname>Wong</surname><given-names>JK</given-names></name>, <name><surname>Smith</surname><given-names>DM</given-names></name>, <name><surname>Pond</surname><given-names>SLK</given-names></name>, <name><surname>Ignacio</surname><given-names>CC</given-names></name>, <etal>et al</etal>
<article-title>Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection</article-title>. <source>J Virol</source>. <year>2008</year>;<volume>82</volume>(<issue>11</issue>):<fpage>5510</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02579-07</pub-id>
<?supplied-pmid 18353964?><pub-id pub-id-type="pmid">18353964</pub-id></mixed-citation></ref><ref id="pone.0171124.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Westreich</surname><given-names>D</given-names></name>, <name><surname>Eron</surname><given-names>J</given-names></name>, <name><surname>Behets</surname><given-names>F</given-names></name>, <article-title>Horst C Van Der, Van Rie A. Survival in Women Exposed to Single-Dose Nevirapine for Prevention of Mother-To-Child Transmission of HIV: A Stochastic Model</article-title>. <source>J Infect Dis</source>. <year>2007</year>;<volume>195</volume>(<issue>6</issue>):<fpage>837</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1086/511276</pub-id>
<?supplied-pmid 17299714?><pub-id pub-id-type="pmid">17299714</pub-id></mixed-citation></ref><ref id="pone.0171124.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Wainberg</surname><given-names>MA</given-names></name>. <article-title>Interactions of Different Drug Resistance Mutations in HIV Reverse Transcriptase in Defining Patterns of Drug Resistance</article-title>. <source>Retrovirology</source>. <year>2011</year>;<volume>8</volume>(<issue>Suppl 2</issue>):<fpage>O14</fpage>.</mixed-citation></ref><ref id="pone.0171124.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Templeton</surname><given-names>AR</given-names></name>, <name><surname>Kramer</surname><given-names>MG</given-names></name>, <name><surname>Jarvis</surname><given-names>J</given-names></name>, <name><surname>Kowalski</surname><given-names>J</given-names></name>, <name><surname>Gange</surname><given-names>S</given-names></name>, <name><surname>Schneider</surname><given-names>MF</given-names></name>, <etal>et al</etal>
<article-title>Multiple-Infection and Recombination in HIV-1 within a Longitudinal Cohort of Women</article-title>. <source>Retrovirology</source>. <year>2009</year>;<volume>6</volume>:<fpage>54</fpage>
<pub-id pub-id-type="doi">10.1186/1742-4690-6-54</pub-id>
<?supplied-pmid 19493346?><pub-id pub-id-type="pmid">19493346</pub-id></mixed-citation></ref><ref id="pone.0171124.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Bello</surname><given-names>G</given-names></name>, <name><surname>Aulicino</surname><given-names>PC</given-names></name>, <name><surname>Ruchansky</surname><given-names>D</given-names></name>, <name><surname>Guimar&#x000e3;es</surname><given-names>ML</given-names></name>, <name><surname>Lopez-Galindez</surname><given-names>C</given-names></name>, <name><surname>Casado</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Phylodynamics of HIV-1 Circulating Recombinant Forms 12_BF and 38_BF in Argentina and Uruguay</article-title>. <source>Retrovirology</source>. <year>2010</year>;<volume>7</volume>:<fpage>22</fpage>
<pub-id pub-id-type="doi">10.1186/1742-4690-7-22</pub-id>
<?supplied-pmid 20307282?><pub-id pub-id-type="pmid">20307282</pub-id></mixed-citation></ref><ref id="pone.0171124.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>C</given-names></name>, <name><surname>Li</surname><given-names>M</given-names></name>, <name><surname>Shi</surname><given-names>Y-P</given-names></name>, <name><surname>Winter</surname><given-names>J</given-names></name>, <name><surname>van Eijk</surname><given-names>AM</given-names></name>, <name><surname>Ayisi</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Genetic Diversity and High Proportion of Intersubtype Recombinants among HIV Type 1-Infected Pregnant Women in Kisumu, Western Kenya</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2004</year>;<volume>20</volume>(<issue>5</issue>):<fpage>565</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1089/088922204323087822</pub-id>
<?supplied-pmid 15186532?><pub-id pub-id-type="pmid">15186532</pub-id></mixed-citation></ref><ref id="pone.0171124.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Lal</surname><given-names>RB</given-names></name>, <name><surname>Chakrabarti</surname><given-names>S</given-names></name>, <name><surname>Yang</surname><given-names>C</given-names></name>. <article-title>Impact of Genetic Diversity of HIV-1 on Diagnosis, Antiretroviral Therapy &#x00026; Vaccine Development</article-title>. <source>Indian J Med Res</source>. <year>2005</year>;<volume>121</volume>(<issue>4</issue>):<fpage>287</fpage>&#x02013;<lpage>314</lpage>. <?supplied-pmid 15817945?><pub-id pub-id-type="pmid">15817945</pub-id></mixed-citation></ref><ref id="pone.0171124.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Pillay</surname><given-names>D</given-names></name>, <name><surname>Bhaskaran</surname><given-names>K</given-names></name>, <name><surname>Jurriaans</surname><given-names>S</given-names></name>, <name><surname>Prins</surname><given-names>M</given-names></name>, <name><surname>Masquelier</surname><given-names>B</given-names></name>, <name><surname>Dabis</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>The Impact of Transmitted Drug Resistance on the Natural History of HIV Infection and Response to First-Line Therapy</article-title>. <source>AIDS</source>. <year>2006</year>;<volume>20</volume>(<issue>1</issue>):<fpage>21</fpage>&#x02013;<lpage>8</lpage>. <?supplied-pmid 16327315?><pub-id pub-id-type="pmid">16327315</pub-id></mixed-citation></ref><ref id="pone.0171124.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Wei</surname><given-names>X</given-names></name>, <name><surname>Youngpairoj</surname><given-names>AS</given-names></name>, <name><surname>Garrido</surname><given-names>C</given-names></name>, <name><surname>Zahonero</surname><given-names>N</given-names></name>, <name><surname>Corral</surname><given-names>A</given-names></name>, <name><surname>de Mendoza</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance</article-title>. <source>J Clin Microbiol</source>. <year>2011</year>;<volume>50</volume>(<issue>2</issue>):<fpage>148</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">22090407</pub-id></mixed-citation></ref><ref id="pone.0171124.ref060"><label>60</label><mixed-citation publication-type="book"><name><surname>Zeh</surname><given-names>C</given-names></name>, <name><surname>Maman</surname><given-names>D</given-names></name>, <name><surname>Omondi</surname><given-names>H</given-names></name>, <name><surname>Morwabe</surname><given-names>A</given-names></name>, <name><surname>Odhiambo</surname><given-names>C</given-names></name>, <name><surname>Kirubi</surname><given-names>B</given-names></name>, <etal>et al</etal>
<source>False recent rates for two recent infection testing algorithms, South Nyanza, Kenya</source>. In: <publisher-name>CROI</publisher-name>
<year>2015</year> p. <fpage>625</fpage>.</mixed-citation></ref><ref id="pone.0171124.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Longosz</surname><given-names>AF</given-names></name>, <name><surname>Serwadda</surname><given-names>D</given-names></name>, <name><surname>Nalugoda</surname><given-names>F</given-names></name>, <name><surname>Kigozi</surname><given-names>G</given-names></name>, <name><surname>Franco</surname><given-names>V</given-names></name>, <name><surname>Gray</surname><given-names>RH</given-names></name>, <etal>et al</etal>
<article-title>Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the Bio-Rad Avidity Assay, and the BED Capture Immunoassay in Rakai, Uganda</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2014</year>;<volume>30</volume>(<issue>4</issue>):<fpage>339</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1089/AID.2013.0169</pub-id>
<?supplied-pmid 24083837?><pub-id pub-id-type="pmid">24083837</pub-id></mixed-citation></ref><ref id="pone.0171124.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Lataillade</surname><given-names>M</given-names></name>, <name><surname>Chiarella</surname><given-names>J</given-names></name>, <name><surname>Yang</surname><given-names>R</given-names></name>, <name><surname>Schnittman</surname><given-names>S</given-names></name>, <name><surname>Wirtz</surname><given-names>V</given-names></name>, <name><surname>Uy</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Na&#x000ef;ve Subjects in the CASTLE Study</article-title>. <source>PLoS One</source>. <year>2010</year>;<volume>5</volume>(<issue>6</issue>):<fpage>e10952</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0010952</pub-id>
<?supplied-pmid 20532178?><pub-id pub-id-type="pmid">20532178</pub-id></mixed-citation></ref><ref id="pone.0171124.ref063"><label>63</label><mixed-citation publication-type="other">Guha SK, Haldar SN. Drug Resistance in HIV. In: Medicine Update. 2012. p. 84&#x02013;8.</mixed-citation></ref><ref id="pone.0171124.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Fisher</surname><given-names>R</given-names></name>, <name><surname>van Zyl</surname><given-names>GU</given-names></name>, <name><surname>Travers</surname><given-names>SAA</given-names></name>, <name><surname>Kosakovsky Pond</surname><given-names>SL</given-names></name>, <name><surname>Engelbrech</surname><given-names>S</given-names></name>, <name><surname>Murrell</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Deep Sequencing Reveals Minor Protease Resistance Mutations in Patients Failing a Protease Inhibitor Regimen</article-title>. <source>J Virol</source>. <year>2012</year>;<volume>86</volume>(<issue>11</issue>):<fpage>6231</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.06541-11</pub-id>
<?supplied-pmid 22457522?><pub-id pub-id-type="pmid">22457522</pub-id></mixed-citation></ref></ref-list></back></article>